Streetbeat News

KYTX

Kyverna Therapeutics Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

4.85

Mkt cap

188M

Volume

279K

High

4.85

P/E Ratio

-2.05

52-wk high

30.60

Low

4.32

Div yield

N/A

52-wk low

4.32

Kyverna Therapeutics has received the U.S. FDA's RMAT designation for its treatment KYV-101, aimed at progressive myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:08 pm

JP Morgan analyst Brian Cheng maintains an Overweight rating on Kyverna Therapeutics (NASDAQ:KYTX) but lowers the price target from $39 to $33.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 6:37 pm

CAR-T cell therapy, traditionally used for blood cancers, shows promise in treating autoimmune diseases like lupus. Despite early success, challenges such as high costs and complex manufacturing processes remain. Companies like Kyverna Therapeutics, Cabaletta Bio, and Allogene Therapeutics are exploring various approaches to make CAR-T more accessible and effective.

Portfolio Pulse from Vandana Singh

July 19, 2024 | 5:45 pm

HC Wainwright & Co. has reiterated a Neutral rating on Kyverna Therapeutics (NASDAQ:KYTX) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:58 am

Several key stocks are expected to grab investor focus today, including Bank of America, Morgan Stanley, FB Financial, Kyverna Therapeutics, and UnitedHealth Group. Bank of America and Morgan Stanley are set to release their earnings reports, while Kyverna Therapeutics received FDA designation for a new treatment.

Portfolio Pulse from Avi Kapoor

July 16, 2024 | 7:08 am

Kyverna Therapeutics shares are trading higher after the company announced it received FDA Regenerative Medicine Advanced Therapy designation for KYV-101 in the treatment of patients with refractory stiff-person syndrome.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:10 pm

Kyverna Therapeutics, Inc. announced that its product candidate KYV-101 has received the U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of refractory stiff-person syndrome. This designation will provide Kyverna with expert guidance on efficient drug development and use of surrogate endpoints.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:07 pm

HC Wainwright & Co. has initiated coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2024 | 10:20 am

Kyverna Therapeutics shares are trading higher after the company announced KYV-101 received FDA IND clearance for the treatment of patients with treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 trial.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:57 pm

The FDA has authorized the clearance for Kyverna's KYV-101 CAR T-cell therapy for the treatment of patients with treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 trial. This expands the use of KYV-101 in targeting B cell-driven autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.